Combination Of Local And Systemic Therapies For Enhanced Treatment of Dermatologic Conditions

Abstract

A treatment for inflammatory dermatoses, such as psoriasis and atopic dermatitis (eczema), is disclosed that utilizes topical administration of a halogenated xanthene, such as rose bengal, together with administration of one or more complementary targeted systemic dermatology therapies, preferably a therapy that addresses the inflammatory pathway and is other than an NSAID that is a COX-1 and / or COX-2 inhibitor. Examples of complementary targeted systemic therapeutic ingredients include: corticosteroids, including betamethasone dipropionate and fluocinonide; dithranol; vitamin D analogs, including calcipotriol; and retinoids, non-biologics including methotrexate, ciclosporin, hydroxycarbamide, and fumarates including dimethyl fumarate; as well as one or more biologics, including antibodies or paratope-containing antibody portions to TNF-α, antibodies to pro-inflammatory cytokines interleukin-12, interleukin-23 and interleukin-17, and TNF inhibitors. Treatment of other epithelial tissue, such as the lining of the gut, is also disclosed.

Description

CROSS-REFERENCE TO RELATED APPLICATION[0001]This application is a continuation of copending U.S. application Ser. No. 16 / 204,832, filed on Nov. 29, 2018 which claims priority to U.S. provisional application Ser. No. 62 / 592,086, filed on Nov. 29, 2017, whose disclosures are incorporated herein by reference.FIELD OF THE INVENTION[0002]This invention relates to the fields of dermatology and improved therapeutic regimens therefore.BACKGROUND OF THE INVENTION[0003]Pharmacologic approaches for treating hyperproliferative or inflammatory dermatologic conditions have traditionally relied on the use of various single agent systemic therapies, single agent topical therapies (monotherapies), or other locally administered modalities like light therapy, all in a rotation to avoid toxicity or intermittently to reduce inflammation and address symptoms which appear often sporadically. These diseases are chronic, lifelong and are difficult to manage.[0004]The underlying disease triggers are difficul...

AI Technical Summary

Benefits of technology

The present invention is the result of combining certain therapeutic modalities through the use of a halogenated xanthene agent (PH-10) and systemic therapies for the treatment of skin diseases. This combination can enhance the effectiveness of both therapies while minimizing adverse effects. The use of complementary therapies can also lead to synergistic interactions that allow for reduced dosages and duration of treatment while maintaining high efficacy. Additionally, combining local therapy with systemic therapy can make the latter more viable, as the benefit of the systemic therapy is enhanced while the adverse effect profile of the local therapy is non-overlapping. This combination therapy is safer and more effective compared to previous combinations that can produce synergistic adverse effects.

Problems solved by technology

These diseases are chronic, lifelong and are difficult to manage.

The underlying disease triggers are difficult to predict and address and lead to a challenge for interventions prior to manifestation of widespread symptoms.

Topical steroids are the most common prescribed treatment for hyperproliferative skin disorders; however, extended use of topical corticosteroid creams may cause thinning of the skin, stretch marks and have systemic effects.

This treatment has the drawback of increasing aging of the skin and susceptibility to skin cancer as well as inconvenience for the patient to attend multiple light therapy sessions in the physician's office.

Newer biologic agents like adalimumab, guselkumab, efalizumab, etanercept, infliximab, abatacept, golimumab and ustekinumab are expensive and have different sets of side effects, notably latent tuberculosis reactivation, increase risk of infection, exacerbation of demyelinating conditions, liver toxicity and cardiovascular complications.

More skin conditions may not be completely responsive to such monotherapy, either due to systemic toxicity necessitating lower dosages or development of resistance that circumvents the activity of the monotherapy agent.

This is further complicated by the lack of clinical studies in children's AD as they are often prescribed medicines approved initially in adults whose underlying disease is potentially driven by other inflammatory markers.

2016 March-April; 29(2):120-125), and combinations are often used in psoriasis (Feldman et al., Am Health Drug Benefits 2016 Dec. 9(9):504-513); however, many of these combinations do not achieve a satisfactory response.

Regardless of the cause, once an aberrant immune-inflammatory response starts, it is difficult to stop with conventional therapies.

Additionally, intradermal injection of rose bengal in the presence of light led to polymorphonuclear leukocyte accumulation and histamine release with accompanying increased erythema in rabbit skin.

Images